TMCC2 and Alzheimer disease: The co‐localization of TMCC2 and APP immunoreactivity within these dense‐core‐associated APP‐positive dystrophies was almost ubiquitous; post hoc analysis showed that co‐localization of TMCC2 and APP immunoreactivity in these dystrophies was common in late onset AD across both APOE genotypes (c.f. Figures 2G and S2B) and more common in APOE3 than APOE4 cases, but rare in early onset AD (see below and Figure S4).